NTSR1 and pachyonychia congenita: Although the value of NTSR1 expression was not assessed in patients with PSMA-negative PET/CT, preclinical in vitro and in vivo studies in PC animal models suggest that PET imaging using specific probes for NTSR1, such as 68Ga-DOTA-NT-20.3 or 18F-DEG-VS-NT could represent viable alternative options for selecting therapies targeting NTSR1 in mCRPC patients with limited PSMA expression levels [60,61].